Article

MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphoma

2018-04-09

Abstract excerpt

Oncogenic MYC activation promotes cellular proliferation in Burkitt lymphoma (BL), but also induces cell cycle arrest and apoptosis mediated by TP53 , a tumor suppressor gene that is mutated in 40% of BL cases. To identify therapeutic targets in BL, we investigated molecular dependencies in BL cell lines using RNAi-based, loss-of-function screening. By integrating genotypic and RNAi data, we identified a number o...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 41f16fad-4d32-5595-bc3a-9dc217af75a0
DOI: 10.1101/289363

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphomaDOI 10.1101/289363Read

MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt LymphomaSemantic proximity Read

Interruption of p53-MDM2 Interaction by Nutlin-3a in Human Lymphoma Cell Models Initiates a Cell-Dependent Global Effect on Transcriptome and Proteome LevelSemantic proximity Read

Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targetsSemantic proximity Read

Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.Semantic proximity Read

Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCLSemantic proximity Read

TP53 mutation heterogeneity reveals distinct prognoses in mantle cell lymphoma.Semantic proximity Read

Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia.Semantic proximity Read

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).Semantic proximity Read

MDM4 is a rational target for treating breast cancers with mutant p53.Semantic proximity Read

Role of genetic and epigenetic changes in Burkitt lymphoma.Semantic proximity Read

Comprehensive Biomarker and Genomic Analysis Identifies p53 Status as the Major Determinant of Response to MDM2 Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read

MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell LymphomaSemantic proximity Read